Skip to main content
SpringerLink
Log in

Long-term management

  • Chapter
Handbook of Osteoporosis

  • 1139 Accesses

Abstract

Pain is a universal result of acute fracture; furthermore, chronic pain is a common complication following hip and vertebral fracture and can have an adverse effect on patients’ quality of life. Nevertheless, older patients are frequently undertreated for fracture pain, with a resultant increase in adverse outcomes [1]. For example, inadequate pain control after hip fracture is associated with poor short- and long-term functional recovery and a longer duration of hospitalization [2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Colón-Emeric CS, Saag KG. Osteoporotic fractures in older adults. Best Pract Res Clin Rheumatol 2006;20:695–706.

    Article  PubMed  Google Scholar 

  2. Morrison RS, Magaziner J, McLaughlin MA, et al. The impact of post-operative pain on outcomes following hip fracture. Pain 2003;103:303–11.

    Article  PubMed  Google Scholar 

  3. Morrison RS, Magaziner J, Gilbert M, et al. Relationship between pain and opioid analgesics on the development of delirium following hip fracture. J Gerontol A Biol Sci Med Sci 2003;58:76–81.

    Article  PubMed  Google Scholar 

  4. Ismail AA, Cooper C, Felsenberg D, et al. Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. Osteoporos Int 1999;9:206–13.

    Article  PubMed  CAS  Google Scholar 

  5. Kim DH, Vaccaro AR. Osteoporotic compression fractures of the spine; current options and considerations for treatment. Spine J. 2006 Sep–Oct; 6:479–87.

    Google Scholar 

  6. Silverman SL. Quality of life issues in osteoporosis. Curr Rheumatol Rep 2005;7:39–45.

    Article  PubMed  Google Scholar 

  7. Harrison JE, Chow R, Dornan J, et al. Evaluation of a program for rehabilitation of osteoporotic patients (PRO): 4-year follow-up. Osteoporos Int 1993;3:13–7.

    Article  PubMed  CAS  Google Scholar 

  8. Helmes E, I-lodsmiiani A, lazowski D, et al. A questionnaire to evaluate disability in osteoporotic patients with vertebral compression fractures. J Gerontol A Biol Sci 1990;50:M191–8.

    Google Scholar 

  9. Reginster JY, Rabenda V. Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. Clin Intervent Aging 2006;1:415–423.

    Article  CAS  Google Scholar 

  10. Segal E, Tamir A, Ish-Shalom S. Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J 2003;5:859–62.

    PubMed  Google Scholar 

  11. Yood RA, Emani S, Reed JI, Lewis BE, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003;14:965–968.

    Article  PubMed  CAS  Google Scholar 

  12. McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271–87.

    Article  PubMed  CAS  Google Scholar 

  13. Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003–1008.

    Article  PubMed  Google Scholar 

  14. Siris E, Rosen CJ, Harris ST, et al. Adherence to bisphosphonate therapy: relationship to bone fractures at 24 months in women with post-menopausal osteoporosis. Presented at the National Osteoporosis Foundation 6th International Symposium on Osteoporosis; April 6–9, 2005; Washington, DC.

    Google Scholar 

  15. Emkey R, Delmas PD, Goemaere S, et al. Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study. Arthritis Rheum 2003;48:1102–8.

    Article  PubMed  CAS  Google Scholar 

  16. International Osteoporosis Foundation (IOF). The adherence gap: why osteoporosis patients don’t continue with treatment. A European report highlighting the gap between the beliefs of people with osteoporosis and the perceptions of their physicians. Nyon: IOF, 2005.

    Google Scholar 

  17. Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med 2006;119(suppl 1):S12–7.

    Article  PubMed  Google Scholar 

  18. Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 2003;14:259–62.

    PubMed  CAS  Google Scholar 

  19. Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg onceweekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging 2000;12:1–12.

    PubMed  CAS  Google Scholar 

  20. Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int. 2002;71:103–111.

    Article  PubMed  CAS  Google Scholar 

  21. Simon JA, Lewiecki EM, Smith ME, et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 2002;24:1871–86.

    Article  PubMed  CAS  Google Scholar 

  22. Kendler D, Kung AW, Fuleihan Gel H, et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 2004;48:243–51.

    Article  PubMed  CAS  Google Scholar 

  23. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80:856–61.

    Article  PubMed  Google Scholar 

  24. Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453–60.

    Article  PubMed  CAS  Google Scholar 

  25. Chesnut III CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241–9.

    Article  CAS  Google Scholar 

  26. Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006;65:654–61.

    Article  PubMed  CAS  Google Scholar 

  27. Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005;21:1895–903.

    Article  PubMed  CAS  Google Scholar 

  28. Hadji P, Benhamou C-L, Devas V, Masanauskaite D, Barrett-Connor E. Women with postmenopausal osteoporosis prefer once-monthly oral ibandronate to weekly oral alendronate: results of BALTO II. Abstract presented at 6th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, Vienna, Austria, 15–18 March 2006.

    Google Scholar 

  29. Hadji P, Minne H, Pfeifer M, et al. Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II). Joint Bone Spine 2008; 75:303–10.

    Article  PubMed  CAS  Google Scholar 

  30. Cooper A, Drake J, Brankin E, et al. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006;60:896–905.

    Article  PubMed  CAS  Google Scholar 

  31. Cuddihy MT, Amadio PC, Gabriel SE, et al. A prospective clinical practise intervention to improve osteoporosis management following distal forearm fracture. Osteoporosis Int 2004;15:695–700.

    Article  Google Scholar 

  32. Gold DT, Silverman SL. Osteoporosis self-management: choices for better bone health. South Med J 2004;97:551–4.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Applied Medicine, University of Aberdeen Medical School, Aberdeen, UK

    David M Reid (Professor of Rheumatology, Head)

Authors
  1. David M Reid
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Healthcare, a part of Springer Science+Business Media

About this chapter

Cite this chapter

Reid, D.M. (2011). Long-term management. In: Handbook of Osteoporosis. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-908517-10-4_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-908517-10-4_8

  • Publisher Name: Springer Healthcare, Tarporley

  • Print ISBN: 978-1-907673-07-8

  • Online ISBN: 978-1-908517-10-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation